NewsNovo
At the midpoint of Eli Lilly and Company's (LLY) 2026 revenue guidance, $86 billion is the number every buy-side model will anchor on. The company has set a range of $85 billion to $87 billion for the year.
What complicates the read is that Lilly is also expanding access through two programs, Foundayo and the Medicare GLP-1 Bridge, and the connection between those investments and the revenue range has not been quantified.
What the guidance says The $85 billion to $87 billion range is a full-year 2026 projection. At that scale, it is a statement about aggregate trajectory.
The guidance sets the bar against which every subsequent quarterly print will be measured.
Keep reading